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nel during standard-of-care visits. Although this is the traditional approach, it has 
several practical shortcomings: infrequent or irregular standard-of-care visits; 
patients switching health care providers; transient nature of some safety events; 
treatment at non-study sites, and the lack of care-seeking for the safety events. An 
alternative study design that overcomes several of these shortcomings includes 
direct-to-patient contact (DPC) and follow-up. Objectives: The purpose of this 
study is to describe patients’ short and long term management patterns including 
the detection and verification of events of interest by contacting patients’ event 
treating physician (ETP). MethOds: This is multinational multicenter observational 
prospective longitudinal cohort study involving 10,600 patients in Europe and South 
America. Patients were enrolled at hospital and followed up by telephone by a spe-
cialized DPC unit at 6 weeks then quarterly up to 2 years after hospital discharge. 
Data collected include clinical outcomes, safety events of interest, economic bur-
den and quality of life. Results: A total of 88,276 phone calls to patients were 
performed, achieving a reachable rate of 88.5% and an interview successful rate of 
84.6%. 87.2% of the initial sample completed the 2-year follow-up period: 5.7% of 
the sample died, 6.0% voluntarily withdrew and 0.9% was withdrawn to participate 
to a clinical trial. Only 19 patients were never reached (0.2%). In total, 2144 events of 
interest were detected and a medical verification from ETPs was obtained in 72.3% of 
the case. cOnclusiOns: This study demonstrates that DPC along with a proactive 
pharmacovigilance system achieved very high response rates from both patients 
and ETPs. It represents an effective alternative methodology to collect patients data, 
including safety data, in real life settings.
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AntithrombotiC StrAtegieS And AdVerSe outComeS in ACute 
CoronAry Syndrome And AtriAl FibrillAtion: A Community Study
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Objectives: Atrial fibrillation (AF) is frequent in acute coronary syndromes (ACS) 
and impacts the need for subsequent antithrombotic treatment. However, whether 
associations of antithrombotic treatment with strokes, bleeding, and death differ 
between ACS patients with and without AF remains uncertain. MethOds: Olmsted 
County, MN residents with incident myocardial infarction or unstable angina during 
2005-2010 were classified according to AF status prior to or during the index ACS 
hospitalization. Antithrombotic strategy at discharge was categorized into double/
triple vs. no/single and warfarin vs. no warfarin therapy. Cox regression was used 
to examine associations between treatment and strokes, bleeding, and mortality 
and to test whether AF differentially impacted these associations. Models were 
age- and sex-adjusted and weighted for the inverse probability of the propensity 
score for therapy. Results: A total of 244 of 1140 incident ACS patients had AF 
(ACS+AF), and of these patients, 49% were discharged on double/triple antithrom-
botic therapy and 33% received warfarin. In 896 ACS patients without AF, 63% were 
discharged on double/triple therapy and 4% on warfarin. Over a median of 4.2 years, 
95 strokes, 297 bleeds, and 255 deaths occurred. Antithrombotic strategy was not 
associated with the risk of stroke or bleeding. Among all ACS patients, mortality 
was similar between strategies; however, ACS+AF patients on double/triple therapy 
(vs. no/single therapy) showed a trend toward a lower risk of death [HR (95% CI): 
0.64 (0.41-1.02) for ACS+AF, 1.25 (0.83-1.87) for those without AF; pinteraction= 0.03]. 
For warfarin vs. no warfarin, those with AF exhibited a lower mortality risk with 
warfarin [HR (95% CI): 0.46 (0.29-0.73) for ACS+AF, 2.01 (0.94-4.32) for those with-
out AF; pinteraction< 0.01]. cOnclusiOns: Altogether, in community ACS patients, 
antithrombotic strategy is not associated with the risk of stroke, bleeding, or death. 
However, in the subset of ACS patients with AF, a warfarin strategy is associated 
with a lower risk of death.
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Objectives: Determine the impact of co-morbidity in controlling arterial hyperten-
sion in clinical practice situation. MethOds: Cross-sectional study, conducted from 
retrospective review of patient records obtained from primary care. We included 
patients’ ≥ 30 years who demanded attention during the year 2012. The main meas-
ures were: demographics, control (≤ 140/90 mmHg) blood pressure (BP), evolution 
time, co-morbidity (general and specific) protocol using cardiovascular events (CVE), 
visits and referrals to specialists. Statistical analysis and multiple linear regression 
for correction of the models, p< 0.05. Results: We recruited 900 patients (mean age 
67.4 years, women: 51.1%). The 64.8% (CI: 61.7% -67.9%) of subjects had a proper 
control of the BP. The average duration of hypertension was 6.0 years and use 4.6 
protocol entries / year. The average number of visits was 15.3 and 0.7 referrals. The 
years of evolution were associated with age (r = 0.323). The control patients showed 
a higher average BP of ischemic heart disease (11.1% vs. 6.9%) and CVE (19.4% vs. 
14.8%), p < 0.05. The BP control was associated with women (OR = 1.4) and the pres-
ence of CVE (OR = 1.8), p < 0.02. The number of diagnoses (morbidity) was associated 
with age (ß = 0.14) and the number of referrals (ß = 0.08), p < 0.05 (coefficient R2= 
40%). cOnclusiOns: Optimal control of BP is high. The profile of these patients is 
women in a situation of secondary prevention.
PCV5
high doSAgeS oF StAtinS in high CArdioVASCulAr riSk PAtientS in A 
reAl World Setting: treAtment PAtternS And outComeS
Degli Esposti L., Sangiorgi D., Buda S.
CliCon Srl, Ravenna, Italy
Objectives: International guidelines recommend the use of high dosages statins 
(in particular, Rosuvastatin and Atorvastatin) in high cardiovascular (CV) risk 
patients. The aim of this study was to assess the degree of implementation of the 
while after first year of treatment, controls tend to become less frequent, mostly 
every-three-months (39.9%). When recurrence occurs, main retreatment criteria 
were: presence of macular fluid (93.5%), loss of ETDRS letters (50.5%; 68.8% with 
≥ 5 letters), macular hemorrhage (46.3%) and increase of central-retinal-thickness 
(45.4%). Single injection of anti-VEGF retreatments was applied in 48.6% of recur-
rences, while 23.6% were not treated with anti-VEGF. cOnclusiOns: A relatively 
high adherence to SERV guidelines was followed by Spanish retinologists regarding 
diagnosis, treatment and control of AMD. However, limitations have been identified 
on patterns of follow-up and retreatment criteria that may compromise therapeutic 
and clinical outcomes.
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treAtment PAtternS oF rAnibizumAb And AFliberCePt For the 
mAnAgement oF Wet Age-relAted mACulAr degenerAtion in routine 
CliniCAl PrACtiCe in the united StAteS
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Objectives: To compare the frequency of injections for ranibizumab and afliber-
cept for the treatment of wet age-related macular degeneration (wAMD) in a real-
world setting. MethOds: Claims from the IMS Integrated Data Warehouse were 
used to identify treatment-naïve patients with wAMD receiving ≥ 1 prescription for 
ranibizumab or aflibercept between 1 November 2011 and 31 March 2012 and with 
a follow-up of 365 days. Patients were considered to be treatment-naïve if they had 
received no anti-VEGF treatment for > 180 days prior to the index date. Mean number 
of injections received within 365 days of treatment initiation and the proportion of 
patients receiving 3 loading doses within 3 months were calculated and compared 
for patients starting therapy with ranibizumab or aflibercept. No adjustments for 
bilateral treatment were performed. Results: Patient characteristics were similar 
for patients receiving ranibizumab (N= 2,799) or aflibercept (N= 117) at the index 
date (median age: 82 years; % male, 36%). The mean (±SD) number of anti-VEGF 
injections received by patients starting on ranibizumab or starting on aflibercept 
was similar: 5.6±3.5 and 5.4±2.8, respectively (p= 0.6593). In patients continuously 
treated with the same agent for 12 months, the mean number of injections was 
also similar across ranibizumab and aflibercept: 4.9±3.4 (n= 1,898) vs 5.2±2.6 (n= 87), 
respectively (p= 0.2705). Approximately two-thirds of patients with more than 3 
injections received 3 loading doses within the first 3 months (ranibizumab, 65.6%; 
aflibercept, 64.3%). Results for patients who were treatment-naïve for 365 days were 
consistent with the above results. cOnclusiOns: There are limited data regard-
ing real-world treatment patterns with aflibercept for the management of wAMD. 
Our results suggest that in routine clinical practice patients receive a comparable 
number of injections in the first year of treatment with both ranibizumab and 
aflibercept. Analysis of data from larger patient populations and for longer follow-
up is warranted when these data become available.
reSeArCh PoSter PreSentAtionS – SeSSion iV 
diSeASe-SPeCiFiC StudieS 
CArdioVASCulAr diSorderS – Clinical outcomes Studies
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APPliCAtion oF logiStiC regreSSion For SignAl deteCtion And riSk 
ASSeSSment oF mACrolide-ASSoCiAted torSAde de PointeS
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: Torsade de pointes (TdP) is an identified risk for antibacterial treat-
ment with macrolides, but the risk might vary across individual macrolides. This 
study evaluates the association between macrolides and TdP from the FDA Adverse 
Event Reporting System (FAERS). MethOds: Disproportionality analysis of FAERS 
between 1997 and 2012 was conducted for azithromycin, clarithromycin, erythro-
mycin and Telithromycin with TdP preferred term of the Medical Dictionary for 
Regulatory Activities using logistic regression. Logistic reporting odds ratio (LROR) 
and corresponding 95% confidence intervals (CIs; LR05-LR95) are estimated for 
individual macrolides. Estimates are compared with Multi-Item Gamma Poisson 
Shrinker data mining algorithm. Estimates ≥ 2 yield significant safety signals. Lack 
of overlap between estimate-specific CIs indicates efficient approach for signal 
detection. Results: A total of 318 TdP events were reported for macrolides. The 
majority of reports were for erythromycin (n= 122) and clarithromycin (n= 114), fol-
lowed by azithromycin (n= 74) and telithromycin (n= 8). Most of events were reported 
for females with median age of 62.8 years. 98% of TdP were serious events (10% of 
those were deaths). Death contributed to 18%, 10% and 5% of serious TdP events 
for azithromycin, erythromycin and clarithromycin, respectively. Telithromycin 
didn’t have death TdP reports. Significant TdP signals were identified for mac-
rolides. LROR (LR05-LR95) were: erythromycin 48.1 (40.4-55.9); clarithromycin 15.3 
(12.1-19.1); azithromycin 13.9 (11.1-17.2); and telithromycin 6.79 (3.20-13.5). Except 
for telithromycin, no overlap was observed between estimate-specific CIs between 
analysis methods. cOnclusiOns: Macrolides are associated with more than 
expected reporting of TdP compared to other drugs and events in the database; 
however, the risk was highest in erythromycin and lowest in telithromycin. Fatal TdP 
was highest in azithromycin, and telithromycin didn’t have fatal TdP. The findings 
show differential risk of TdP across macrolide antibiotics, emphasizing the need for 
monitoring cardiac rhythms in patients treated with macrolides.
PCV2
direCt-to-PAtient ContACt And ProACtiVe PhArmACoVigilAnCe 
SyStem: A CASe Study
Wiederkehr S., Seux M., Michel J., Fournie X.
Mapi, Lyon, France
Post-authorization non-interventional safety studies typically enroll patients at 
sites and safety events are reported and collected as appropriate by site person-
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patients, riociguat increased the proportion fulfilling criteria defining a positive 
response to therapy.
PCV8
PAtient rePorted outComeS ASSSeSment oF thAi ChroniC StAble 
AnginA PeCtoriS(CSAP)
Rojkajornnaphalai S.
Chest Hospital, Nonthaburi, Thailand
Objectives: A pilot test to assess patient-centered outcomes in daily manage-
ment of coronary artery disease at cardiology clinics in Thailand. MethOds: A 
Delphi method was used for development of PRO questionnaire assessing along 
with ivabradine treatment from randomly selected CSAP patients under the Health 
Authorities’ pharmacovigilance monitoring program. A 15-items short-form health 
survey with 5 response choices adopted with permission from validity-tested PRO 
used in medical outcomes study in Thai patients, four health dimensions included 
general, physical, social function role limiting and mental health dimensions with 
1, 6, 5 and 3 items each respectively. Standardized scoring was calculated with 
the lowest(0) to highest(100). Field tests among healthy volunteers performed.The 
reliability test employed inter-item and intra-item consistency using Cronbach’s 
alpha coefficient. All 15 items of survey were evaluated at initiation and after 
four months clinical intervention. The treatment acceptability was further 
assessed from patient interviews. Results: Of 162 patients randomly selected 
for PRO evaluation, 85(53%) was men, all patients mean(SD) age of 67.3(11.7) years 
whom 97(59.5%)was > 65 years, 9(5.5%) was smokers and 81(49.7%) had a Body 
Mass Index ≥ 25 kg/m2. Forty-three (26.4%) of patients had previous intervention 
and 63(39%) had heart failure(HF). The internal consistency of the score for all 
15 items, for physical, social function role limiting and mental health dimen-
sions, reflected Chronbach’s alpha coefficient of 0.888, 0.771, 0.702 and 0.807 at 
baseline. After 4-month, Cronbach’s alpha coefficient were of 0.735, 0.715, 0.661 
and 0.519. All mean scores(SD) of these four health dimensions, were signifi-
cantly improved from 47.59(11.50) to 54.91(9.45), from 50.33(12.11) to 54.91(10.42), 
from 39.53(10.35) to 52.68(10.32) and from 45.88(17.08) to 54.88(18.49) respectively 
(P< 0.001). cOnclusiOns: This pilot development confirms reliability of 15-items 
short-form health survey, score is consistent overtime. Thai CSAP patients who 
were prescribed ivabradine reported a highly significant improvement in qual-
ity of life including all health dimensions general, physical, social function role 
limiting and mental health. Patient-reported outcomes questionnaires could be 
recommended alongside clinical treatment.
PCV9
AttAinment oF loW-denSity liPoProtein CholeSterol goAlS in 
PAtientS At Very high CArdioVASCulAr riSk in the united kingdom: 
reSultS From A generAl PrACtiCe PoPulAtion Study
Ray K.K.1, Foody J.2, Khan I.3, Lewis B.E.4
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Objectives: European guidelines support LDL-C goals based on an individual’s 
absolute cardiovascular (CV) risk and have established a goal of < 70 mg/dL in very 
high CV risk patients. The objective of this study was to estimate the proportion of 
individuals that attain these goals and assess the determinants of any observed 
variation. MethOds: Patients in The Health Improvement Network (THIN) UK 
general practice database with an LDL-C measurement during 2011 and at very 
high risk of CV risk events were identified and further categorized as recent acute 
coronary syndrome (ACS, within 6 months pre LDL-C measurement), prior coronary 
events, stroke, and peripheral vascular disease (PVD). Lipid-lowering therapy (LLT) 
was categorized as high-potency statin, standard-potency statin, non-statin LLT, 
and no LLT. Results: In total, 25,535 patients met the inclusion criterion. Median 
(inter-quartile range [IQR]) age was 71 (62 to 79) years, 63.5% were male, and median 
(IQR) LDL-C was 108 (83 to 139) mg/dL. Across the total cohort, 6.3%, 61.3%, 17.8%, and 
14.6% had evidence of recent ACS, prior coronary events, stroke, and PVD. Patients 
with LDL-C < 70 mg/dL within these categories were 18.9%, 13.5%, 14.5%, and 11.4%. 
Across the total cohort, 16.0%, 52.5%, 0.5%, and 31.0% were on high-potency statin, 
standard-potency statin, non-statin LLT, and no LLT. Patients with LDL-C < 70 mg/
dL within these LLT categories were 18.3%, 15.4%, 11.6%, and 8.5%. cOnclusiOns: 
In a large, contemporary cohort of very high CV risk patients, few achieved the 
optimal LDL-C goal of < 70 mg/dL. One third were not on any LLT, < 20% were on 
high-potency statin, and > 80% of those receiving high-potency statins were not at 
LDL-C goal. These data suggest the need for ongoing efforts to improve prescribing 
of appropriate LLT as well as identifying new therapies to improve goal attainment 
among very high CV risk patients.
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VenouS thromboemboliSm in gynAe-onCology PAtientS PoSt Surgery 
– iS tinzAPArin ProPhylAxiS An eFFeCtiVe AntiCoAgulAnt?
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Objectives: Venous thromboembolism (VTE) is a relatively common post-operative 
complication in cancer patients associated with high mortality rates. Gynae-oncology 
patients are predisposed to developing VTE due to the presence of a number of high 
risk factors. Current thromboprophylactic protocols for LMWH dosage and duration 
may be insufficient as a significant percentage of VTEs in gynae-oncology patients 
occur despite LMWH prophylaxis. The aim of this study is to investigate the antico-
agulant (anti-Xa) activity of Tinzaparin prophylaxis in the immediate post-operative 
period in gynae-oncology patients. MethOds: All patients attending St. James’s 
recommended therapeutic strategies and clinical outcomes as a function of the 
therapeutic strategies in a real world setting. MethOds: An observational retro-
spective cohort analysis based on 4 Local Health Units administrative databases 
was conducted. High CV risk patients who filled at least one prescription for high 
dosages statins between January 1, 2007-December 31, 2007 (enrolment period) 
were included. Patients were followed-up for 24 months. Patients were defined as 
adherent if they had > 80% of follow up period covered by drugs dispensation. To 
correct for potential confounders, a multivariable proportional hazards Cox regres-
sion model considering age, gender, type of statin, adherence to treatment and 
stay on treatment was assessed. Stay on treatment was defined as no switch or 
down titration during the follow up period. Results: Among 36,327 (3% of the 
population) high CV risk patients, Rosuvastatin 40mg (R40) and Atorvastatin 80mg 
(A80) were not used (0.1% each treatment); 625 (2%) patients used R20 and 908 (2%) 
A40. Stay on treatment was similar across treatments: 61% for R20 and 60% for A40 
(p= 0.583). 2.6 (1.7-3.5) CV events per 100 patients/year for R20 and 4.4 (3.4-5.4) for 
A40 were observed (p= 0.014). At the multivariable Cox regression analysis, risk of 
CV event was lower for R20, as compared to A40 (HR= 0.60, 95%CI 0.39-0.91, p= 0.017). 
Other statistically significant covariates were adherence (HR= 0.50, 95%CI 0.29-0.87, 
p= 0.015) and stay on treatment (HR= 0.58, 95%CI 0.40-0.85, p= 0.006). cOnclusiOns: 
Despite guidelines recommendations, high dosages statins are poorly used in real 
practice. Stay on treatment was similar among those treated with R20 and A40, even 
though R20 showed a lower incidence of cardiovascular events.
PCV6
modeling the CArdioVASCulAr eFFeCtS oF SWitChing PAtientS From 
roSuVAStAtin to AtorVAStAtin
Folse H.1, Schuetz C.A.1, Rengarajan B.1, Sternhufvud C.2, Gandhi S.K.3
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Objectives: This analysis estimates the impact of switching from rosuvastatin 
to atorvastatin on cardiovascular (CV) events. MethOds: Using the Archimedes 
model, a discrete-event simulation, we evaluated a simulated population of 50,038 
patients aged 45–70 years with dyslipidemia and adherent to rosuvastatin. The 
virtual population was created based on matched biomarker profiles of patients 
in the National Health and Nutrition Examination Survey (NHANES). Statin treat-
ment models were based on data from published studies, including STELLAR, 
JUPITER, CARDS, ASCOT, and TNT. Patients were started on a rosuvastatin dose 
based on their LDL-C and ATP-III goal. Treatment prevalence was calibrated to 
match distributions of statin use observed in U.S. pharmacy claims data. In the 
experimental arm, patients switched to twice the mg atorvastatin dose as their 
rosuvastatin dose at their first follow-up visit (no switching occurred in the con-
trol arm). Patients were monitored for 5 years, during which time they received 
regular visits, with the opportunity to increase their dosage if they were above 
their LDL-C goal. Rate of first occurrence of MI, stroke, or CV death (MACE) for 
each arm was estimated. Results: After 5 years, when all patients switched to 
atorvastatin, 4.8% fewer patients reached goal, and mean LDL-C increased by 7.1 
mg/dL. The 5-year relative risk of MACE was 1.117 (95% CI 1.098–1.135), and the 
number needed to harm (NNH) to incur one additional MACE was 262, favoring 
rosuvastatin. For diabetics, the relative risk of MACE was 1.128 (95% CI 1.096–1.159), 
and the NNH to incur one additional MACE was 195, indicating greater risk for dia-
betics. The results were insensitive to assumptions of adherence rates and LDL-C 
goal values. cOnclusiOns: In this simulation, switching from rosuvastatin to 
atorvastatin led to fewer patients attaining LDL-C goal, higher mean LDL-C values, 
and greater risk of MACE over 5 years.
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rioCiguAt For the treAtment oF PAtientS With PulmonAry ArteriAl 
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PAtientS From the PAtent-1 Study
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Objectives: Indications for PAH medications vary between countries, and prod-
ucts may have restricted reimbursement based on policies limiting treatment to 
WHO functional class (FC) III patients. In the PATENT-1 study, the novel soluble 
guanylate cyclase stimulator riociguat significantly improved 6-minute walking 
distance (6MWD) and a range of secondary endpoints in patients with PAH. This 
subgroup analysis of PATENT-1 investigated the proportion of FC III/IV patients 
achieving threshold criteria. MethOds: PATENT-1 was a double-blind, randomized 
Phase III study in which patients with PAH received 12 weeks’ oral treatment with 
placebo, an individual titration of riociguat (up to 2.5 mg tid), or a capped titration 
of riociguat (up to 1.5 mg tid). Increase in 6MWD ≥ 40 m, 6MWD ≥ 380 m, cardiac 
index (CI) ≥ 2.5 L/min/m2, pulmonary vascular resistance (PVR) < 500 dyn·s·cm−5, 
mixed venous oxygen saturation (SvO2) ≥ 65%, FC I/II, absence of clinical worsen-
ing events, and NT-proBNP < 1800 pg/mL were chosen as positive response criteria 
based on studies showing their prognostic relevance at baseline and after targeted 
therapy. Results: At baseline, 241 patients were in FC III/IV (FC IV n= 4) across 
the three treatment groups, and similar proportions met selected criteria in the 
riociguat individual titration (n= 141) and placebo groups (n= 61). At Week 12/last 
visit, the proportion of patients fulfilling these criteria was higher in the riociguat 
individual titration group than the placebo group for all parameters: increase in 
6MWD ≥ 40m (44% vs 15%), 6MWD ≥ 380m (49% vs 36%), CI ≥ 2.5 L/min/m2 (75% vs 
43%), PVR < 500 dyn·s·cm−5 (52% vs 27%), SvO2 ≥ 65% (68% vs 35%), FC I/II (33% vs 
23%), absence of clinical worsening events (99% vs 90%), and NT-proBNP < 1800 pg/
mL (84% vs 64%). cOnclusiOns: In this population of predominantly FC III PAH 
